What is Foundayo, and where has it been launched?

Foundayo is Eli Lilly's oral weight-loss and type 2 diabetes treatment, chemically known as orforglipron; it has been launched in the UK, making it the first country in Europe where the drug is available after receiving authorization from Britain's medicines regulator on August 10.

How does Foundayo's pricing compare to Lilly's injectable Mounjaro in the UK?

Foundayo will likely be priced between £100 and £120 per month in the UK, which is lower than Lilly's injectable Mounjaro, priced at £330 for a month's supply.

Eli Lilly Launches Oral Weight-Loss Pill Foundayo in UK

Aug 23, 2026

Eli Lilly launched its oral weight-loss drug Foundayo (orforglipron) in the UK, marking the first European availability and offering a lower price point than injectable alternatives while pending EU review.

reuters

2026-02-03

Feb. 3 Business Watch: Catalysis start-ups raise money; Lilly strikes deals with 2 biotech firms

2026-03-31

Eli Lilly to Acquire Narcolepsy Drug Developer for $6.3 Billion

2026-04-29

Eli Lilly Investors Eager for Foundayo Insight After Early Launch Data

2026-04-30

Lilly lifts profit forecast as surging demand for weight-loss drugs offsets pricing pressure

2026-04-30

US Premarket Movers for April 30, 2026